Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
Wednesday, March 05, 2025Tiziana Life Sciences Ltd a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate intranasal foralumab a fully human antiCD monoclonal antibody today announced the submission of its Investigation...
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Wednesday, March 05, 2025Capricor Therapeutics a biotechnology company developing transformative cell and exosomebased therapeutics for the treatment of rare diseases today announced the US Food and Drug Administration FDA has accepted for review its Biologics License Applic...
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Tuesday, March 04, 2025Genevant Sciences a leading nucleic acid delivery company with worldclass platforms and a robust lipid nanoparticle LNP patent portfolio a subsidiary of Roivant Sciences Ltd Nasdaq ROIV and Arbutus Biopharma Corporation Nasdaq ABUS a clinicalstage bi...
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
Tuesday, March 04, 2025SciSparc Ltd a specialty clinicalstage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system announced it has signed a definitive agreement to sell its entire ownership interest in MitoCareX...
Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies
Monday, March 03, 2025Roche announced today new positive data from Stage and Stage of the National Institutes of Health NIHsponsored phase III OUtMATCH study which provide further evidence supporting the role of Xolair omalizumab for the treatment of one or more food al...
Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable non-small cell lung cancer
Monday, March 03, 2025AstraZenecas Imfinzi durvalumab in combination with chemotherapy has been recommended for approval in the European Union EU for the treatment of adults with resectable nonsmall cell lung cancer NSCLC at high risk of recurrence and no epidermal growth...
Enhertu recommended for approval in the EU by CHMP for patients with HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy
Saturday, March 01, 2025AstraZeneca and Daiichi Sankyos trastuzumab deruxtecan has been recommended for approval in the European Union EU as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor HRpositive HERlow or HERultralow b...
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor
Saturday, March 01, 2025Eli Lilly and Companyannounced today that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has issued a positive opinion for Jaypirca pirtobrutinib a noncovalent reversible Brutons tyrosine kinase
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
Saturday, March 01, 2025Moderna Inctoday announced that the Medicines and Healthcare products Regulatory Agency MHRA in the UK has granted marketing authorization for mRESVIA mRNA indicated for active immunization for the prevention of lower respiratory
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Saturday, March 01, 2025Roche announced today that the European Medicines Agencys Committee for Medicinal Products for Human Use CHMP has recommended the approval of Columvi glofitamab in combination with gemcitabine and oxaliplatin GemOx for the treatment
